home / stock / alrn / alrn quote
Last: | $2.54 |
---|---|
Change Percent: | -0.39% |
Open: | $2.49 |
Close: | $2.55 |
High: | $2.62 |
Low: | $2.41 |
Volume: | 11,568 |
Last Trade Date Time: | 07/29/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.54 | $2.49 | $2.55 | $2.62 | $2.41 | 11,568 | 07-29-2024 |
$2.55 | $2.52 | $2.55 | $2.74 | $2.5 | 56,065 | 07-26-2024 |
$2.51 | $2.62 | $2.51 | $2.62 | $2.51 | 34,678 | 07-25-2024 |
$2.65 | $2.67 | $2.65 | $2.9099 | $2.64 | 5,763 | 07-24-2024 |
$2.75 | $2.75 | $2.75 | $2.89 | $2.6 | 38,326 | 07-23-2024 |
$2.77 | $2.71 | $2.77 | $3.1 | $2.71 | 15,397 | 07-22-2024 |
$2.74 | $3 | $2.74 | $3.01 | $2.7 | 129,101 | 07-19-2024 |
$2.8 | $2.99 | $2.8 | $3.005 | $2.8 | 40,973 | 07-18-2024 |
$2.99 | $3.13 | $2.99 | $3.13 | $2.96 | 14,263 | 07-17-2024 |
$3.09 | $2.93 | $3.09 | $3.1 | $2.93 | 37,576 | 07-16-2024 |
$2.98 | $3.15 | $2.98 | $3.18 | $2.77 | 95,921 | 07-15-2024 |
$3.18 | $3.1 | $3.18 | $3.25 | $3.01 | 77,022 | 07-12-2024 |
$3.09 | $3.13 | $3.09 | $3.22 | $3.0001 | 78,866 | 07-11-2024 |
$3.06 | $3.24 | $3.06 | $3.3 | $3.06 | 120,942 | 07-10-2024 |
$3.16 | $3.01 | $3.16 | $3.24 | $2.9268 | 97,829 | 07-09-2024 |
$3.11 | $2.72 | $3.11 | $3.15 | $2.714 | 123,848 | 07-08-2024 |
$2.87 | $2.69 | $2.87 | $3.15 | $2.69 | 229,536 | 07-05-2024 |
$2.84 | $2.81 | $2.84 | $2.87 | $2.72 | 18,175 | 07-04-2024 |
$2.84 | $2.81 | $2.84 | $2.87 | $2.72 | 18,175 | 07-03-2024 |
$2.76 | $2.83 | $2.76 | $2.84 | $2.7001 | 12,949 | 07-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
Aileron Therapeutics Inc. Company Name:
ALRN Stock Symbol:
NASDAQ Market:
Aileron Therapeutics Inc. Website:
Aileron Therapeutics to be Included in the Russell Microcap® Index PR Newswire AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of...
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...